Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19.
Adolescent
Adrenal Cortex Hormones
/ therapeutic use
Adult
Aged
Aged, 80 and over
Algeria
/ epidemiology
Biomarkers
/ blood
C-Reactive Protein
/ metabolism
COVID-19
/ epidemiology
Female
Ferritins
/ blood
Humans
Inflammation Mediators
/ blood
Interleukin-2 Receptor alpha Subunit
/ blood
Interleukin-6
/ blood
Lymphocyte Count
Male
Middle Aged
Neutrophils
/ immunology
Pandemics
Predictive Value of Tests
Procalcitonin
/ blood
Prognosis
Prospective Studies
SARS-CoV-2
Severity of Illness Index
Young Adult
COVID-19 Drug Treatment
COVID-19
Cytokine storm
IL6
Inflammatory biomarker
NLR
Procalcitonin
Journal
Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
15
09
2020
revised:
08
01
2021
accepted:
09
01
2021
pubmed:
8
2
2021
medline:
30
3
2021
entrez:
7
2
2021
Statut:
ppublish
Résumé
Accumulating evidence supports that the viral-induced hyper-inflammatory immune response plays a central role in COVID-19 pathogenesis. It might be involved in the progression to acute respiratory distress syndrome (ARDS), multi-organ failure leading to death. In this study, we aimed to evaluate the prognostic value of the immune-inflammatory biomarkers in COVID-19, then determine optimal thresholds for assessing severe and fatal forms of this disease.153 patients with confirmed COVID-19 were included in this study, and classified into non-severe and severe groups. Plasmatic levels of interleukin 6 (IL6), C-reactive protein (CRP), soluble-IL2 receptor (IL2Rα), procalcitonin (PCT) and ferritin were measured using chemiluminescence assay. Complete blood count was performed by Convergys 3X® hematology analyzer. Our results demonstrated that the peripheral blood levels of IL6, PCT, CRP, ferritin, IL2Rα, white blood cell count (WBC), neutrophil count (NEU), neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (d-NLR) were significantly higher in severe forms of COVID-19. The ROC curve analysis showed that IL6 was the most accurate inflammatory biomarker. The calculated cutoff of IL6 (42 pg/ml) could correctly classify > 90% of patients regarding their risk of severity (area under ROC curve (AUROC) = 0.972) and the threshold value of 83 pg/ml was highly predictive of the progression to death (AUROC = 0.94, OR = 184) after a median of 3 days. Besides, IL-6 was positively correlated with other inflammatory markers and the kinetic analysis highlighted its value for monitoring COVID-19 patients. PCT and NLR had also a high prognostic relevance to assess severe forms of COVID-19 with corresponding AUROC of 0.856, 0.831 respectively. Furthermore the cut-off values of PCT (0.16 ng/ml) and NLR (7.4) allowed to predict mortality with high accuracy (se = 96.3%, sp = 70.5%,OR = 61.2)' (se = 75%, sp = 84%, OR = 14.6).The levels of these parameters were not influenced by corticosteroid treatment, which make them potential prognostic markers when patients are already undergoing steroid therapy.
Identifiants
pubmed: 33550165
pii: S1043-4666(21)00008-9
doi: 10.1016/j.cyto.2021.155428
pmc: PMC7834734
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Biomarkers
0
IL2RA protein, human
0
IL6 protein, human
0
Inflammation Mediators
0
Interleukin-2 Receptor alpha Subunit
0
Interleukin-6
0
Procalcitonin
0
C-Reactive Protein
9007-41-4
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
155428Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
J Infect. 2020 Jul;81(1):e6-e12
pubmed: 32283162
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Aging Cell. 2020 Jul;19(7):
pubmed: 32558150
Lancet Respir Med. 2014 Aug;2(8):611-20
pubmed: 24853585
Intensive Care Med. 2018 Nov;44(11):1859-1869
pubmed: 30291376
Immunol Lett. 2020 Sep;225:31-32
pubmed: 32569607
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Clin Chim Acta. 2020 Jun;505:190-191
pubmed: 32145275
Int J Infect Dis. 2020 Jun;95:332-339
pubmed: 32334118
Immunol Invest. 2021 Jan;50(1):92-100
pubmed: 32482134
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
Am J Respir Crit Care Med. 2017 Feb 1;195(3):331-338
pubmed: 27513822
Breathe (Sheff). 2019 Dec;15(4):296-304
pubmed: 31803264
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
J Pharm Anal. 2020 Apr;10(2):102-108
pubmed: 32282863
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Med Virol. 2020 Jul;92(7):856-862
pubmed: 32281668
Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
pubmed: 32445579
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
J Med Virol. 2020 Jul;92(7):791-796
pubmed: 32181911
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Expert Rev Anti Infect Ther. 2018 Jul;16(7):555-564
pubmed: 29969320
JCI Insight. 2020 May 21;5(10):
pubmed: 32324595
Sci Rep. 2015 Jun 16;5:11355
pubmed: 26079127
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
J Immunol. 2008 Aug 1;181(3):2189-95
pubmed: 18641358
J Infect. 2020 Sep;81(3):452-482
pubmed: 32526326
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
Int J Antimicrob Agents. 2020 Aug;56(2):106017
pubmed: 32437920